Form 4: Acrivon Therapeutics Executive Sells Shares to Cover Tax Obligations

Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, sold 402 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Erick Gamelin, the Chief Development Officer of Acrivon Therapeutics, sold 402 shares of common stock on November 14, 2024.
• The sale was executed at a price of $7.92 per share.
• This transaction was to cover mandatory tax withholding requirements upon the vesting of restricted stock units.
• Following the transaction, Gamelin directly owns 16,961 shares of Acrivon Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no significant positive or negative implications for the company's outlook.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting insider transactions in publicly traded companies.
• The sale of shares to cover tax obligations is a common occurrence when restricted stock units vest.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale for tax purposes.

Key Dates

Keywords

Acrivon Therapeutics, Erick Gamelin, stock sale, insider trading, Form 4, tax withholding, restricted stock units